These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Eide PW; Bruun J; Lothe RA; Sveen A Sci Rep; 2017 Nov; 7(1):16618. PubMed ID: 29192179 [TBL] [Abstract][Full Text] [Related]
5. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000 [TBL] [Abstract][Full Text] [Related]
6. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675 [TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524 [TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of cell lines from chromosomal instable colorectal cancer. Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089 [TBL] [Abstract][Full Text] [Related]
9. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146 [TBL] [Abstract][Full Text] [Related]
10. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues. de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602 [TBL] [Abstract][Full Text] [Related]
11. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226 [TBL] [Abstract][Full Text] [Related]
12. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965 [TBL] [Abstract][Full Text] [Related]
13. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models. Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914 [TBL] [Abstract][Full Text] [Related]
14. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988 [TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741 [TBL] [Abstract][Full Text] [Related]
16. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155. Zhan T; Faehling V; Rauscher B; Betge J; Ebert MP; Boutros M Int J Cancer; 2021 Apr; 148(8):1948-1963. PubMed ID: 33186476 [TBL] [Abstract][Full Text] [Related]
17. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study. González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108 [TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Lazzari L; Corti G; Picco G; Isella C; Montone M; Arcella P; Durinikova E; Zanella ER; Novara L; Barbosa F; Cassingena A; Cancelliere C; Medico E; Sartore-Bianchi A; Siena S; Garnett MJ; Bertotti A; Trusolino L; Di Nicolantonio F; Linnebacher M; Bardelli A; Arena S Clin Cancer Res; 2019 Oct; 25(20):6243-6259. PubMed ID: 31375513 [TBL] [Abstract][Full Text] [Related]